Importer of Controlled Substances Application: Nexus Pharmaceuticals, Inc., 72793-72794 [2023-23320]
Download as PDF
<![CDATA[
72793
Federal Register / Vol. 88, No. 203 / Monday, October 23, 2023 / Notices
the Joint Board for enrollment purposes
and acceptable to the other two actuarial
organizations as part of their respective
examination programs.
2. Scope of Advisory Committee Duties
The Advisory Committee plays an
integral role in the examination program
by assisting the Joint Board in offering
examinations that enable examination
candidates to demonstrate the
knowledge necessary to qualify for
enrollment. The Advisory Committee’s
duties, which are strictly advisory,
include (1) recommending topics for
inclusion on the Joint Board
examinations, (2) developing and
reviewing examination questions, (3)
recommending proposed examinations,
(4) reviewing examination results and
recommending passing scores, and (5)
providing other recommendations and
advice relative to the examinations, as
requested by the Joint Board.
lotter on DSK11XQN23PROD with NOTICES1
3. Member Terms and Responsibilities
Generally, members are appointed for
a 2-year term. However, the member
selected pursuant to this notice will be
appointed for 12 months, beginning
March 1, 2024. Members may seek
reappointment for additional
consecutive terms.
Members are expected to attend
approximately 4 meetings each calendar
year and are reimbursed for travel
expenses in accordance with applicable
government regulations. For this
appointment, the member is expected to
attend approximately 4 meetings.
Meetings may be held in-person or by
teleconference. In general, members are
expected to devote 125 to 175 hours,
including meeting time, to the work of
the Advisory Committee over the course
of a year.
4. Member Selection
The Joint Board seeks to appoint an
Advisory Committee that is fairly
balanced in terms of points of view
represented and functions to be
performed. Every effort is made to
ensure that most points of view extant
in the enrolled actuary profession are
represented on the Advisory Committee.
To that end, the Joint Board seeks to
appoint members from each of the main
practice areas of the enrolled actuary
profession, including small employer
plans, large employer plans, and
multiemployer plans. In addition, to
ensure diversity of points of view, the
Joint Board limits the number of
members affiliated with any one
actuarial organization or employed with
any one firm.
Membership normally will be limited
to actuaries currently enrolled by the
VerDate Sep<11>2014
17:24 Oct 20, 2023
Jkt 262001
Joint Board. However, individuals
having academic or other special
qualifications of particular value for the
Advisory Committee’s work also will be
considered for membership. Federally
registered lobbyists and individuals
affiliated with Joint Board enrollment
examination preparation courses are not
eligible to serve on the Advisory
Committee.
5. Member Designation
Advisory Committee members are
appointed as Special Government
Employees (SGEs). As such, members
are subject to certain ethical standards
applicable to SGEs. Upon appointment,
each member will be required to
provide written confirmation that he/
she does not have a financial interest in
a Joint Board examination preparation
course. In addition, each member will
be required to attend annual ethics
training.
6. Application Requirements
To receive consideration, an
individual interested in serving on the
Advisory Committee must submit (1) a
signed, cover letter expressing interest
in serving on the Advisory Committee
and describing his/her professional
qualifications, and (2) a resume and/or
curriculum vitae. Applications must be
submitted electronically to NHQJBEA@
irs.gov. The transmittal email should
include APPLICATION FOR ADVISORY
COMMITTEE in the subject line.
Applications must be received by
December 1, 2023.
Dated: October 18, 2023.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. 2023–23328 Filed 10–20–23; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1284]
Importer of Controlled Substances
Application: Nexus Pharmaceuticals,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Nexus Pharmaceuticals, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before November 22, 2023. Such
persons may also file a written request
for a hearing on the application on or
before November 22, 2023.
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on September 20, 2023,
Nexus Pharmaceuticals, Inc., 10300
128th Avenue, Pleasant Prairie,
Wisconsin 53158–7336 applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
Remifentanil ..................
9739
II
The company plans to import the
listed controlled substance for research
and analytical testing purposes. No
other activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
E:\FR\FM\23OCN1.SGM
23OCN1
72794
Federal Register / Vol. 88, No. 203 / Monday, October 23, 2023 / Notices
approved finished dosage forms for
commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–23320 Filed 10–20–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2010–0013]
SolarPTL, LLC: Application for
Expansion of Recognition
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Notice.
AGENCY:
In this notice, OSHA
announces the application of SolarPTL,
LLC, for expansion of the scope of
recognition as a Nationally Recognized
Testing Laboratory (NRTL) and presents
the agency’s preliminary finding to
grant the application.
DATES: Submit comments, information,
and documents in response to this
notice, or requests for an extension of
time to make a submission, on or before
November 7, 2023.
ADDRESSES: Comments may be
submitted as follows:
Electronically: You may submit
comments, including attachments,
electronically at https://
www.regulations.gov, the Federal
eRulemaking Portal. Follow the online
instructions for submitting comments.
Instructions: All submissions must
include the agency’s name and the
docket number for this rulemaking
(Docket No. OSHA–2010–0013). All
comments, including any personal
information you provide, are placed in
the public docket without change and
may be made available online at https://
www.regulations.gov. Therefore, OSHA
cautions commenters about submitting
information they do not want made
available to the public, or submitting
materials that contain personal
information (either about themselves or
others), such as Social Security numbers
and birthdates.
Docket: To read or download
comments or other material in the
docket, go to https://
www.regulations.gov. Documents in the
docket (including this Federal Register
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:24 Oct 20, 2023
Jkt 262001
notice) are listed in the https://
www.regulations.gov index; however,
some information (e.g., copyrighted
material) is not publicly available to
read or download through the website.
All submissions, including copyrighted
material, are available for inspection
through the OSHA Docket Office.
Contact the OSHA Docket Office at (202)
693–2350 (TTY (877) 889–5627) for
assistance in locating docket
submissions.
Extension of comment period: Submit
requests for an extension of the
comment period on or before November
7, 2023 to the Office of Technical
Programs and Coordination Activities,
Directorate of Technical Support and
Emergency Management, Occupational
Safety and Health Administration, U.S.
Department of Labor, 200 Constitution
Avenue NW, Room N–3653,
Washington, DC 20210, or by fax to
(202) 693–1644.
FOR FURTHER INFORMATION CONTACT:
Information regarding this notice is
available from the following sources:
Press inquiries: Contact Mr. Frank
Meilinger, Director, OSHA Office of
Communications, U.S. Department of
Labor, telephone: (202) 693–1999;
email: meilinger.francis2@dol.gov.
General and technical information:
Contact Mr. Kevin Robinson, Director,
Office of Technical Programs and
Coordination Activities, Directorate of
Technical Support and Emergency
Management, Occupational Safety and
Health Administration, U.S. Department
of Labor, phone: (202) 693–2300 or
email: robinson.kevin@dol.gov.
SUPPLEMENTARY INFORMATION:
I. Notice of the Application for
Expansion
OSHA is providing notice that
SolarPTL, LLC. (PTL), is applying for an
expansion of current recognition as a
NRTL. PTL requests the addition of one
test standard to the NRTL scope of
recognition.
OSHA recognition of a NRTL signifies
that the organization meets the
requirements specified in 29 CFR
1910.7. Recognition is an
acknowledgment that the organization
can perform independent safety testing
and certification of the specific products
covered within the scope of recognition.
Each NRTL’s scope of recognition
includes (1) the type of products the
NRTL may test, with each type specified
by the applicable test standard and (2)
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
the recognized site(s) that has/have the
technical capability to perform the
product-testing and productcertification activities for test standards
within the NRTL’s scope. Recognition is
not a delegation or grant of government
authority; however, recognition enables
employers to use products approved by
the NRTL to meet OSHA standards that
require product testing and certification.
The agency processes applications by
a NRTL for initial recognition, as well
as for an expansion or renewal of
recognition, following requirements in
Appendix A to 29 CFR 1910.7. This
appendix requires that the agency
publish two notices in the Federal
Register in processing an application. In
the first notice, OSHA announces the
application and provides the
preliminary finding. In the second
notice, the agency provides the final
decision on the application. These
notices set forth the NRTL’s scope of
recognition or modifications of that
scope. OSHA maintains an
informational web page for each NRTL,
including PTL, which details that
NRTL’s scope of recognition. These
pages are available from the OSHA
website at https://www.osha.gov/dts/
otpca/nrtl/.
PTL currently has one facility (site)
recognized by OSHA for product testing
and certification, with the headquarters
located at: SolarPTL, LLC, 1107 West
Fairmont Drive, Tempe, Arizona 85282.
A complete listing of PTL’s scope of
recognition is available at https://
www.osha.gov/nationally-recognizedtesting-laboratory-program/solarptl.
II. General Background on the
Application
PTL submitted an application, dated
June 1, 2021 (OSHA–2010–0013–0005),
to expand recognition as a NRTL to
include one additional test standard.
OSHA staff performed a detailed
analysis of the application packet and
reviewed other pertinent information.
OSHA performed an on-site assessment
related to this application on August
16–17, 2022, where OSHA found
nonconformances with the requirements
of 29 CFR 1910. PTL addressed the
nonconformances adequately and OSHA
has no objection to the addition of this
standard to the scope of recognition.
Table 1 shows the test standard found
in PTL’s application for expansion for
testing and certification of products
under the NRTL Program.
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 88, Number 203 (Monday, October 23, 2023)]
[Notices]
[Pages 72793-72794]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-23320]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1284]
Importer of Controlled Substances Application: Nexus
Pharmaceuticals, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Nexus Pharmaceuticals, Inc. has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
November 22, 2023. Such persons may also file a written request for a
hearing on the application on or before November 22, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on September 20, 2023, Nexus Pharmaceuticals, Inc.,
10300 128th Avenue, Pleasant Prairie, Wisconsin 53158-7336 applied to
be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Remifentanil.......................... 9739 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance for
research and analytical testing purposes. No other activities for these
drug codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-
[[Page 72794]]
approved finished dosage forms for commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-23320 Filed 10-20-23; 8:45 am]
BILLING CODE P
